Sun, Dec 21, 2014, 3:15 PM EST - U.S. Markets closed

Recent

% | $
Quotes you view appear here for quick access.

Exelixis, Inc. Message Board

  • wilderguide wilderguide Mar 14, 2013 12:02 PM Flag

    Radioiodine-Refractory Differentiated Thyroid Cancer

    $$$$
    Another NCI-sponsored P2 study was added yesterday at clinicaltrialsdotgov.
    Currently #16 of 36...
    GLTA

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • $$$$

      I had to revisit this one.
      Here's the official title:

      A Phase II Study of Cabozantinib in Patients With Radioiodine-Refractory Differentiated Thyroid Cancer Who Progressed on First-Line VEGFR-Targeted Therapy

      The list of indicated patient recruiting parameters includes every stage of progressive papillary and follicular DTC. The list of recruiting centers is long and geographically adept - too long to substantiate the indicated enrollment of only 25 patients. The PI and the list of supporting staff clinicians represent the foremost oncologists in thyroid cancer treatment. I'm prepared to go out on a limb here...
      ...and suggest that this may be our label expansion trial - easily expanded to accomodate a listing into the NCCN compendia with virtually no changes to trial infrastructure.
      Good things ahead.
      GLTA

 
EXEL
1.33-0.02(-1.48%)Dec 19 4:00 PMEST

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.
Aegerion Pharmaceuticals, Inc.
NASDAQFri, Dec 19, 2014 4:00 PM EST
ImmunoGen, Inc.
NASDAQFri, Dec 19, 2014 4:00 PM EST
Linn Co, LLC
NASDAQFri, Dec 19, 2014 3:59 PM EST